Highest-materiality recent filing
Autolus Q1 2026: AUCATZYL net revenue $26.2M; positive gross margin; reaffirms FY revenue $120-135M
Net product revenue $26.2M (vs $9.0M Q1 2025); gross profit $1.6M, first positive quarter for ALL business.
Autolus cuts workforce 13%; expects $8M restructuring charge, $15M annualized savings
Reduces workforce ~13% as part of operational efficiency plan; impacted employees receive severance and benefits.
Autolus reports FY2025 AUCATZYL net revenue $74.3M; guides FY2026 $120-135M
Q4 2025 AUCATZYL net revenue $23.3M; full-year $74.3M, primarily from U.S. sales.
Autolus reports preliminary 2025 AUCATZYL rev $75M; guides FY2026 $120-135M
Preliminary unaudited AUCATZYL net product revenue: Q4 2025 ~$24M, full year 2025 ~$75M.
Autolus Q3 net product revenue $21.1M; RMAT for pediatric ALL; lupus data show 83% remission
Q3 2025 net product revenue of $21.1M and deferred revenue of $7.6M; net loss of $79.1M ($0.30 per share).
Autolus reports Q2 AUCATZYL revenue $20.9M; EU/UK approvals secured but Germany launch on hold
Net product revenue $20.9M in Q2, $29.9M H1 2025; 46 U.S. centers activated, >90% medical lives covered.
On May 23, 2025, Drs. Joseph Anderson and Martin Murphy, members of the Board of Directors (the “Board”) of Autolus Therapeutics plc (the “Company”), notified the Company of their intention not to stand for re-election at the Company’s 2025 Annual General Meeting of Shareholders.
On May 23, 2025, Drs. Joseph Anderson and Martin Murphy, members of the Board of Directors (the “Board”) of Autolus Therapeutics plc (the “Company”), notified the Company of their intention not to stand for re-election at the Company’s 2025 Annual General Meeting of Shareholders.
Max materiality 0.75 · Median 0.55 · Most common event earnings